The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jul. 1, 1:03 PM

Slide #20. GlycoMimetics, Inc. Secondary Offering

Company: GlycoMimetics, Inc. (NASDAQ:GLYC)
Date announced: 6/16/2016
Shares Offered: 3,300,000
Date of Pricing: 6/17/2016
Price Per Share: $6.10
Secondary Offering Details: GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. -updated 6/17- GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 3,300,000 shares of its common stock at a price to the public of $6.10 per share. The net proceeds from the offering to GlycoMimetics are expected to be $18.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by GlycoMimetics. The offering is expected to close on or about June 22, 2016, subject to customary closing conditions. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated and SunTrust Robinson Humphrey, Inc. are acting as co-managers for the offering. GlycoMimetics has granted to the underwriters a 30-day option to purchase up to 495,000 additional shares of common stock at the public offering price, less the underwriting discount.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing its principal drug candidate, rivipansel, for the treatment of vaso-occlusive crisis. Co. is also developing its second drug candidate, GMI-1271, to be used in combination with chemotherapy to treat acute myeloid leukemia. Co. has an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. In addition, Co. is also developing other preclinical-stage programs.

GLYC SEC Filing Email Alerts Service

Open the GLYC Page at The Online Investor »

Company Name:  GlycoMimetics Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding GLYC:  2
Total Market Value Held by ETFs:  $205597
Total Market Capitalization:  $139.00M
% of Market Cap. Held by ETFs:  0.15%

Open the GLYC Page at The Online Investor (in a new window) »

July 1, 2016    1:03 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
97th percentile
(ranked higher than approx. 97% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.